Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Myriad Genetics Inc

(NASDAQ: MYGN)
Add to Portfolio
-0.24 (-1.21%)
as of 16:00 EST

Last 19.65
Change -0.24 (-1.21%)
Open 19.85
Prev. Close 19.89
Today's Range
19.62
20.14
52wk Range
19.08
48.40
Volume 556,518
Avg Volume 1,329,597
Sector SIC-2835 In Vitro & In Vivo Diagnostic Substances

Perfomance Comparison

Name Today 3-Month 1-Year
MYGN -1.21% -21.42% -37.98%
DJIA -0.78% +3.81% +12.08%
S&P 500 -1.05% +6.38% +20.22%

Key Statistics

Annual EPS -0.36
Dividend Yield 0.00%
P/E Ratio 26.30
Market Capitalization, $K 1,490,260
Weighted Alpha -23.65
Standard Deviation -0.16
Profit Margin 25.05%
Beta 0.99

Growth Rates

YTD -27.80%
1-Year -38.63%
3-Year +4.79%
5-Year -41.62%
10-Year -13.52%

Opinion

Sell Hold Buy

Recent Headlines

Steer Clear Of These 5 Toxic Stocks Before It's Too

ZACKS - Mon Feb 17, 09:31AM EST
Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.(full story)
MYGN: 19.65 (-0.24), HLIT: 6.65 (-0.12), CSII: 40.21 (-2.37), MIME: 46.40 (-1.77), IAC: 228.19 (-5.37)

Myriad Genetics (MYGN) Releases Favorable Prolaris

ZACKS - Mon Feb 17, 07:46AM EST
This study result is a major breakthrough and is expected to strengthen Myriad Genetics' (MYGN) Oncology segment.(full story)
SYK: 224.30 (-0.17), RMD: 173.88 (-2.12), MYGN: 19.65 (-0.24), HRC: 106.26 (-0.90)

New Study Demonstrates the Ability of Prolaris(R) to

GlobeNewswire via COMTEX - Fri Feb 14, 07:05AM EST
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it is presenting new data at the American Society of Clinical Oncology Genitouranary Cancer Symposium in San Francisco,(full story)
MYGN: 19.65 (-0.24)

Myriad Genetics (MYGN) Files for myChoice CDx Test

ZACKS - Thu Feb 13, 10:36AM EST
With the receipt of the regulatory approval, Myriad Genetics (MYGN) will be taking a major stride forward in its Oncology and Women's Health segment.(full story)
SYK: 224.30 (-0.17), RMD: 173.88 (-2.12), MYGN: 19.65 (-0.24), HRC: 106.26 (-0.90)

Myriad Genetics to Present at the SVB Leerink Global

GlobeNewswire via COMTEX - Wed Feb 12, 07:05AM EST
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:(full story)
MYGN: 19.65 (-0.24)